Nevirapine vs. Atazanavir Boosted With Ritonavir on a Background of Truvada in Human Immunodeficiency Virus (HIV) Infected Naive Patients (NEwArT)
Public ClinicalTrials.gov record NCT00552240. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Official title
Comparison Atazanavir/Ritonavir (ATV/r) vs Nevirapine (NVP) Twice a Day (Bid) on Truvada Backbone
Brief summary
Reproduced verbatim from the official ClinicalTrials.gov record. Not medical advice.
The aim of this clinical trial is to compare the efficacy and safety of ritonavir (RTV)-boosted atazanavir with nevirapine, each on a background of emtricitabine and tenofovir disoproxil fumarate (DF).
Study identification
- NCT ID
- NCT00552240
- Recruitment status
- Completed
- Study type
- Interventional
- Phase
- Phase 4
- Enrollment
- 154 participants
Conditions and interventions
Conditions
Interventions
- tenofovir DF 300 mg QD Drug
- emtricitabine 200 mg QD Drug
- Nevirapine 200 mg BID Drug
- Atazanavir 300 mg Drug
- Ritonavir 100 mg Drug
Drug
Eligibility (public fields only)
- Age range
- 18 Years and older
- Sex
- All
- Healthy volunteers
- Healthy volunteers not accepted
This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.
Study timeline
- Start date
- Aug 31, 2007
- Primary completion
- Feb 28, 2010
- Completion
- Not listed
- Last update posted
- Jan 26, 2014
Started 2007
United States locations
- U.S. sites
- 19
- U.S. states
- 11
- U.S. cities
- 18
| Facility | City | State | ZIP | Site status |
|---|---|---|---|---|
| 1100.1512.28 Boehringer Ingelheim Investigational Site | Beverly Hills | California | — | — |
| 1100.1512.20 Boehringer Ingelheim Investigational Site | Los Angeles | California | — | — |
| 1100.1512.15 Boehringer Ingelheim Investigational Site | Denver | Colorado | — | — |
| 1100.1512.26 Boehringer Ingelheim Investigational Site | Washington D.C. | District of Columbia | — | — |
| 1100.1512.17 Boehringer Ingelheim Investigational Site | Fort Lauderdale | Florida | — | — |
| 1100.1512.14 Boehringer Ingelheim Investigational Site | Orlando | Florida | — | — |
| 1100.1512.23 Boehringer Ingelheim Investigational Site | Vero Beach | Florida | — | — |
| 1100.1512.29 Boehringer Ingelheim Investigational Site | Maywood | Illinois | — | — |
| 1100.1512.11 Boehringer Ingelheim Investigational Site | Neptune City | New Jersey | — | — |
| 1100.1512.25 Boehringer Ingelheim Investigational Site | Newark | New Jersey | — | — |
| 1100.1512.18 Boehringer Ingelheim Investigational Site | Somers Point | New Jersey | — | — |
| 1100.1512.22 Boehringer Ingelheim Investigational Site | Winston-Salem | North Carolina | — | — |
| 1100.1512.21 Boehringer Ingelheim Investigational Site | Philadelphia | Pennsylvania | — | — |
| 1100.1512.13 Boehringer Ingelheim Investigational Site | Charleston | South Carolina | — | — |
| 1100.1512.30 Boehringer Ingelheim Investigational Site | Dallas | Texas | — | — |
| 1100.1512.19 Boehringer Ingelheim Investigational Site | Fort Worth | Texas | — | — |
| 1100.1512.16 Boehringer Ingelheim Investigational Site | Houston | Texas | — | — |
| 1100.1512.24 Boehringer Ingelheim Investigational Site | Houston | Texas | — | — |
| 1100.1512.27 Boehringer Ingelheim Investigational Site | Annandale | Virginia | — | — |
Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.
Recently updated HIV Infections trials
Other public records listing HIV Infections. Sorted by last update posted; newest first. Not a recommendation.
- NCT07650916: A Study to Investigate Cabotegravir Ultra Long-Acting (CAB ULA) Plus Rilpivirine Ultra Long-Acting (RPV ULA) in Adults and Adolescents With HIV Who Are Virologically Suppressed Recruiting
- NCT06679751: Infectious Disease (ID) Testing OUtreach in Carceral Hubs Active, not recruiting
- NCT05996471: A Study to Investigate the Virologic Efficacy and Safety of VH3810109 + Cabotegravir Compared to Standard of Care (SOC) in Male and Female Adults Living With Human Immunodeficiency Virus (HIV) Active, not recruiting
- NCT03729778: Impact of HIV-1 and Aging on Mucosal Vaccine Responses Active, not recruiting
- NCT07728123: Screen2Prevent (S2P) Recruiting
- NCT06316739: The Ganchero Intervention for Migrant People Who Inject Drugs From Puerto Rico in New York City Active, not recruiting
About this trial record page
- What this page shows
- Public field values for ClinicalTrials.gov record NCT00552240, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
- What this page does not do
- No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
- Where the data comes from
- Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
- Last refresh
- Last update posted Jan 26, 2014 · Synced Sep 1, 2026
Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.
Open the official record
The complete protocol, eligibility criteria, and contact information for NCT00552240 live on ClinicalTrials.gov.